Andrew Lewin

Summary

Publications

  1. doi request reprint Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus
    Andrew J Lewin
    National Research Institute, 2010 Wilshire Blvd, Suite 302, Los Angeles, CA 90057, USA 1 213 413 2500 1 213 486 1494
    Expert Opin Pharmacother 16:781-4. 2015
  2. pmc Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age
    Andrew J Lewin
    National Research Institute, 2010 Wilshire Blvd Ste 302, Los Angeles, CA 90057, USA
    Drugs Aging 30:549-60. 2013
  3. doi request reprint Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial
    Andrew Lewin
    National Research Institute, Los Angeles, CA 90057, USA
    Clin Ther 35:142-52. 2013
  4. doi request reprint Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial
    Andrew J Lewin
    National Research Institute, Los Angeles, California 90057, USA
    Clin Ther 34:1909-19.e15. 2012
  5. doi request reprint Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial
    Andrew Lewin
    National Research Institute, Los Angeles, CA 90057, USA
    J Am Soc Hypertens 6:228-36. 2012
  6. doi request reprint Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
    Andrew Lewin
    National Research Institute, Los Angeles, CA
    Diabetes Care 38:394-402. 2015

Detail Information

Publications6

  1. doi request reprint Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus
    Andrew J Lewin
    National Research Institute, 2010 Wilshire Blvd, Suite 302, Los Angeles, CA 90057, USA 1 213 413 2500 1 213 486 1494
    Expert Opin Pharmacother 16:781-4. 2015
    ..SGLT2 inhibitors are not the only therapeutic option in this clinical situation; however, based on the secondary effects observed in this and other studies, they appear to be of particular value for patients who are obese or overweight. ..
  2. pmc Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age
    Andrew J Lewin
    National Research Institute, 2010 Wilshire Blvd Ste 302, Los Angeles, CA 90057, USA
    Drugs Aging 30:549-60. 2013
    ..Hypertension is often inadequately controlled in older people...
  3. doi request reprint Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial
    Andrew Lewin
    National Research Institute, Los Angeles, CA 90057, USA
    Clin Ther 35:142-52. 2013
    ..Elevated systolic blood pressure (SBP) is an independent risk factor for cardiovascular events and mortality...
  4. doi request reprint Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial
    Andrew J Lewin
    National Research Institute, Los Angeles, California 90057, USA
    Clin Ther 34:1909-19.e15. 2012
    ..This study was designed to assess the utility of adjunctive therapy with the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in patients with T2DM inadequately controlled with SU monotherapy...
  5. doi request reprint Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial
    Andrew Lewin
    National Research Institute, Los Angeles, CA 90057, USA
    J Am Soc Hypertens 6:228-36. 2012
    ..Nebivolol withdrawal resulted in a mean BP increase near pretreatment levels and was not associated with rebound hypertension...
  6. doi request reprint Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
    Andrew Lewin
    National Research Institute, Los Angeles, CA
    Diabetes Care 38:394-402. 2015
    ..To evaluate the efficacy and safety of empagliflozin/linagliptin in subjects with type 2 diabetes...